Bioventus shares rise after Medicare reverses reimbursement cuts

Investing.com -- Bioventus Inc. shares climbed as much as 13% on Monday, reaching the highest intraday level since 2024. The increase followed an announcement that the Centers for Medicare & Medicaid Services reversed previously issued reimbursement cuts for the company's non-invasive bone growth stimulators.

You May Also Be Interested In

• General Dynamics wins $47.6m in Navy contract modifications
• Gentherm and Modine set key dates for Performance Technologies deal
• Alphabet (GOOGL) PT Raised to $485 at Tigress Financial Partners